home All News open_in_new Full Article

Novo Nordisk consigue la autorización de la EMA para el uso de una de sus terapias contra la obesidad en niños

La agencia ha concedido una ampliación de indicación para Saxenda. Más información: Dimite el CEO de Novo Nordisk, Lars Fruergaard Jørgensen


today 6 d. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Culture
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics


ID: 1229940592
Add Watch Country

arrow_drop_down